Analyst consensus rating
Zevra Therapeutics Analyst Rating: none
Direct answer
Zevra Therapeutics's consensus rating is none.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $25.00.
Forecast evidence checked September 9, 2026.
Get free Zevra Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $12.68
- Average price target
- $25.00
- High price target
- $35.00
- Low price target
- $20.00
- Low target gap
- +57.8%
- Target upside
- +97.2%
- High target gap
- +176.1%
- Target range width
- 118.3%
- Consensus rating
- none
- Analysts
- 9
- Evidence date
- September 9, 2026
- Valid through
- September 16, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Zevra Therapeutics?
Zevra Therapeutics has a verified none consensus. The same dataset has an average price target of $25.00.
How far are Zevra Therapeutics's low and high targets from the recorded price?
The low target implies +57.8%, while the high target implies +176.1%.
How many analysts are included in Zevra Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is Zevra Therapeutics's target upside or downside calculated?
The average target of $25.00 is divided by the recorded price of $12.68, then one is subtracted to produce +97.2%. This does not guarantee a future return.
When was Zevra Therapeutics's analyst forecast verified?
The data was verified on 2026-09-09. The dataset is valid through 2026-09-16.